Gilead has signed a three-year deal with Google’s life science division Verily to work on identifying the immunological and molecular drivers behind three inflammatory diseases.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.